India, June 18 -- Bengaluru-based startupEyestemResearch has announced the completion of its phase one study for its investigational retinal pigment epithelium (RPE) cell therapy,Eyecyte-RPE.

The clinical study report of the study has been submitted to the Central Drugs Standard Control Organisation (CDSCO) for permission to start the phase 2 study.

The trial, designed to evaluate the safety and efficacy ofEyecyte-RPEin patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD), has shown promising outcomes in the initial phase.

"Our phase 1/2a trial demonstrated an excellent safety profile with no serious adverse events, while delivering clinically meaningful vision improvement-an average of 15.8...